Oral contraceptives moderately effect bone resorption markers and serum-soluble interleukin-6 receptor concentrations.
This study investigated the effect of ethinylestradiol(EE2)-containing oral contraceptives on mineral and bone metabolism and on serum soluble-interleukin-6-receptor (sIL-6R) during the menstrual cycle. Twelve women, aged 24.3 +/- 2.9 years, were examined. Blood and 24-hour and fasting urine samples were obtained during one menstrual cycle between cycle day 3-5 (t(1)), cycle day 10-12 (t(2)), cycle day 24-26 (t(3)), and again on day 3-5 of the next cycle (t(4)). EE2 intake was 0 mg at t(1), 30 mg at t(2), 30 mg at t(3) and 0 mg at t(4). Fasting renal phosphorus and calcium excretions were slightly reduced at t(2) and t(3) compared with t(1) and t(4) (P < 0.05-0.001). Moreover, renal excretion of the bone resorption marker C-Teleopeptide was at t(3) reduced by 26% compared with t(1)(P < 0.01) and by 13% compared with t(4)(P > 0.05). Fasting sIL-6R levels were 16.5% lower at t(2) and 12% lower at t(3) than at t(4) (P < 0.01 and P < 0.05). sIL-6R was correlated with total deoxypyridinoline excretion (r = +0.35; P < 0.05) and with fasting renal excretions of calcium (r = +0.36; P < 0.05) and phosphorus (r = +0.29; P < 0.05). In summary, our data suggest that in young women, cyclic monthly oral contraceptive intake is associated with small, but significant variations in bone resorption processes and in serum sIL-6R levels. Results are a further indication that monthly fluctuations of bone resorption in young women are mediated by sex hormones and that osteoclastic activity is stimulated by cytokines in vivo.
Zittermann
A
A
Department of Nutrition Science, University of Bonn, Endenicher Allee 11-13, 53115 Bonn, Germany.
Rühl
J
J
Berthold
H K
HK
Sudhop
T
T
van der Ven
H
H
Reinsberg
J
J
Stehle
P
P
D000328:Adult; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001862:Bone Resorption / Q000097:blood* / Q000139:chemically induced*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D003276:Contraceptives, Oral / Q000009:adverse effects*; D045166:Estradiol Congeners / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D008597:Menstrual Cycle / Q000502:physiology; D010455:Peptides / Q000652:urine; D019947:Receptors, Interleukin-6 / Q000097:blood*
D015415:Biomarkers; D024042:Collagen Type I; D003276:Contraceptives, Oral; D045166:Estradiol Congeners; D012739:Gonadal Steroid Hormones; D010455:Peptides; D019947:Receptors, Interleukin-6; C052929:collagen type I trimeric cross-linked peptide; D004997:Ethinyl Estradiol; D003094:Collagen